Bio-Thera reports positive data from solid tumors therapy trial

Bio-Thera Solutions has reported positive Phase I clinical data evaluating BAT8006 for the treatment of advanced solid tumors.

An antibody-drug conjugate (ADC), BAT8006 is made of an anti-FRα antibody and an ADC linker-payload combination that consists of a cleavable linker, which is claimed to be highly systemically stable and a small molecule topoisomerase I inhibitor.